{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:30:26Z","timestamp":1787898626867,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejca.2022.07.026","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T11:33:00Z","timestamp":1661686380000},"page":"200-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Detection of ALK fusion variants by RNA-based NGS and clinical outcome\u00a0correlation in NSCLC patients treated with ALK-TKI sequences"],"prefix":"10.1016","volume":"174","author":[{"given":"Fabrizio","family":"Tabb\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Anna","family":"Muscarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gobbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Trombetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8688-9530","authenticated-orcid":false,"given":"Stefano","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Rigutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-5906","authenticated-orcid":false,"given":"Domenico","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-8465","authenticated-orcid":false,"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vieri","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Gregorc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-3148","authenticated-orcid":false,"given":"Concetta","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-4874","authenticated-orcid":false,"given":"Sara","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-0335","authenticated-orcid":false,"given":"Alessandro","family":"Del Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cappuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-7369","authenticated-orcid":false,"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bareggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-1218","authenticated-orcid":false,"given":"Giulio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2333-704X","authenticated-orcid":false,"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0719-105X","authenticated-orcid":false,"given":"Marco","family":"Volante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-958X","authenticated-orcid":false,"given":"Giorgio Vittorio","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-204X","authenticated-orcid":false,"given":"Luisella","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2022.07.026_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"7153","key":"10.1016\/j.ejca.2022.07.026_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ejca.2022.07.026_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ejca.2022.07.026_bib4","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.07.026_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/JTO.0b013e318209edb9","article-title":"Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH","volume":"6","author":"Yi","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.07.026_bib6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jtho.2017.01.020","article-title":"A sensitive ALK immunohistochemistry companion diagnostic test identifies patients eligible for treatment with crizotinib","volume":"12","author":"Thorne-Nuzzo","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.07.026_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jtho.2017.11.117","article-title":"Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European thoracic oncology platform lungscape project","volume":"13","author":"Letovanec","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.07.026_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/modpathol.2017.181","article-title":"Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer","volume":"31","author":"Rosenbaum","year":"2018","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.ejca.2022.07.026_bib9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jtho.2020.02.023","article-title":"Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC","volume":"15","author":"Li","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.07.026_bib10","doi-asserted-by":"crossref","first-page":"e000548","DOI":"10.1136\/esmoopen-2019-000548","article-title":"From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer","volume":"4","author":"Pirker","year":"2019","journal-title":"ESMO Open"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2022.07.026_bib11","doi-asserted-by":"crossref","first-page":"e000524","DOI":"10.1136\/esmoopen-2019-000524","article-title":"How I treat ALK-positive non-small cell lung cancer","volume":"4","author":"McCusker","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.07.026_bib12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s12094-020-02290-1","article-title":"Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine","volume":"22(9)","author":"Remon","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.07.026_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/1759-7714.12791","article-title":"Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer","volume":"9","author":"Kang","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2022.07.026_bib14","first-page":"100040","article-title":"Identification of a novel ALK variant intrinsically resistant to crizotinib","volume":"2","author":"Batra","year":"2020","journal-title":"Curr Probl Cancer: Case Reports"},{"issue":"6","key":"10.1016\/j.ejca.2022.07.026_bib15","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.21037\/tlcr-20-372","article-title":"Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won","volume":"9","author":"Tabb\u00f2","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"28","key":"10.1016\/j.ejca.2022.07.026_bib16","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.07.026_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.07.026_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.31893","article-title":"Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma","volume":"144","author":"Christopoulos","year":"2019","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2022.07.026_bib19","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s10147-021-01916-w","article-title":"Are all ALK variants created equal? Clinicopathologic features and outcomes: a propensity-matched study","volume":"26","author":"Batra","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.07.026_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12094-019-02222-8","article-title":"Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study","volume":"22","author":"Gobbini","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2022.07.026_bib21","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","article-title":"Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2022.07.026_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jmoldx.2013.03.001","volume":"15","author":"Lindeman","year":"2013","journal-title":"J Mol Diagn"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.026_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"Lindeman","year":"2018","journal-title":"J Mol Diagn"},{"issue":"11","key":"10.1016\/j.ejca.2022.07.026_bib24","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.18632\/oncotarget.23800","article-title":"Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression","volume":"9","author":"Trombetta","year":"2018","journal-title":"Oncotarget"},{"issue":"282","key":"10.1016\/j.ejca.2022.07.026_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.ejca.2022.07.026_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer"},{"issue":"10048","key":"10.1016\/j.ejca.2022.07.026_bib27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(16)31340-X","article-title":"Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease","volume":"388","author":"Hiley","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2022.07.026_bib28","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.026_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11523-019-00631-x","article-title":"Distribution of ALK fusion variants and correlation with clinical outcomes in Chinese patients with non-small cell lung cancer treated with crizotinib","volume":"14","author":"Su","year":"2019","journal-title":"Targeted Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.07.026_bib30","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.07.026_bib31","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/JTO.0b013e3182598af3","article-title":"A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK","volume":"7","author":"Penzel","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.07.026_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lungcan.2021.07.020","article-title":"Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance","volume":"160","author":"Liu","year":"2021","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.07.026_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/JTO.0000000000000061","article-title":"HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma","volume":"9","author":"Hong","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2022.07.026_bib34","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with No mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2022.07.026_bib35","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/ijc.31275","article-title":"EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer","volume":"142","author":"Christopoulos","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.07.026_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2017.12.004","article-title":"ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer","volume":"116","author":"McLeer-Florin","year":"2018","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.07.026_bib37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","article-title":"Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer","volume":"14","author":"Pacheco","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.07.026_bib38","first-page":"9517","article-title":"Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L","volume":"38","author":"Camidge","year":"2020","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ejca.2022.07.026_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11912-020-00989-6","article-title":"Upfront management of ALK-rearranged metastatic non-small cell lung cancer: one inhibitor fits all?","volume":"23","author":"Tabb\u00f2","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.026_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/ph14020080","article-title":"Therapeutic sequencing in ALK+ NSCLC","volume":"14","author":"Elsayed","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejca.2022.07.026_bib41","first-page":"2021","article-title":"Circulating cell-free DNA as a prognostic biomarker in patients with advanced ALK+ non-small cell lung cancer in the global phase III ALEX trial","author":"Dziadziuszko","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:00Z","timestamp":1760733480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922004506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":41,"alternative-id":["S0959804922004506"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of ALK fusion variants by RNA-based NGS and clinical outcome\u00a0correlation in NSCLC patients treated with ALK-TKI sequences","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}